CFO
ROIV icon

Callan Family Office’s Roivant Sciences ROIV Stock Holding History

Callan Family Office’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$534K Buy
15,099
+78
+0.5% +$2.31K 0.01% 794
2026
Q1 		$416K Buy
15,021
+56
+0.4% +$1.44K 0.01% 829
2025
Q4 		$325K Buy
+14,965
New +$295K 0.01% 903

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Callan Family Office's ROIV Position: Q2 2026 in Review

Callan Family Office increased its Roivant Sciences (ROIV) stake by 0.52% in Q2 2026, buying an estimated $2.31K and bringing the position to 15,099 shares worth $534K. The position accounts for 0.01% of the portfolio, ranked #794.

Callan Family Office first reported a position in ROIV in Q4 2025 and has held it in 3 quarters since. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Callan Family Office held 15,099 shares of Roivant Sciences worth $534K as of Q2 2026.
  • Callan Family Office bought 78 Roivant Sciences shares in Q2 2026, an estimated $2.31K.
  • Roivant Sciences made up 0.01% of Callan Family Office's portfolio in Q2 2026, its #794 holding.
  • Callan Family Office first reported a position in Roivant Sciences in Q4 2025 and has held it in 3 quarters since.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.